Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis

• Päätekijät: Clémence Bertold (Tekijä), Laura Troin (Tekijä), Madleen Chassang (Tekijä), Thierry Passeron (Tekijä), Jérôme Doyen (Tekijä), Henri Montaudié (Tekijä), Alexandra Picard‐Gauci (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2023-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible...